Psilocybin's Lasting Antidepressant Effects May Rely on Neuronal Activity, Not Brain Structure

A new study has uncovered how psilocybin may produce long-lasting antidepressant effects in rats. Rather than creating permanent structural changes in the brain, the research suggests the drug alters neuronal activity for months after a single dose. These findings add to a growing body of work exploring psilocybin's potential in treating depression.

The study focused on male rats and found that psilocybin modified the intrinsic electrical properties of neurons. This shift persisted long after any physical changes, such as the growth of new neural connections, had disappeared. Researchers observed no lasting difference in the number of dendritic spines between treated and control animals, indicating that structural changes were only temporary.

Further investigation revealed that activating the 5-HT2A receptor alone might be enough to trigger these long-term effects. The team noted that future studies should include both male and female subjects to confirm whether the results apply broadly.

This research builds on a wave of recent psilocybin studies between 2021 and 2026. Landmark trials from institutions like Johns Hopkins University, Imperial College London, and the University of Zurich have shown that a single dose can produce antidepressant effects lasting months. Regulatory progress has followed, with Switzerland granting approval and the US, Canada, and parts of Europe advancing clinical trials or expanded access programmes for treatment-resistant depression.

The findings suggest that psilocybin's benefits may come from lasting changes in how neurons function rather than structural rewiring. With clinical research accelerating worldwide, these insights could help refine how the drug is used in future depression treatments. Further studies will need to test the effects across different populations and conditions.